KRAS 基因突变和 p53 表达对结直肠癌患者术后预后的影响。
Effect of KRAS mutations and p53 expression on the postoperative prognosis of patients with colorectal cancer.
机构信息
Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China.
Department of Surgical Oncology, Fujian Provincial Hospital, Fuzhou, China.
出版信息
Mol Genet Genomic Med. 2022 Jul;10(7):e1905. doi: 10.1002/mgg3.1905. Epub 2022 Jun 10.
BACKGROUND
In the occurrence and development of colorectal cancer, p53 is an important regulator downstream of the MAPK signaling pathway and plays an important role in inhibiting abnormal proliferation signals generated by KRAS mutations. The purpose of this study is to explore the correlation between KRAS mutations and p53 expression and evaluate their prognosis values in colorectal cancer.
METHODS
PCR technology and immunohistochemical (IHC) staining were used to detect KRAS mutation status and p53 expression level in 266 specimens of colorectal adenocarcinoma. Based on p53 expression level, these were divided into high expression and normal groups. Patients with KRAS mutations were divided into mutant and wild-type groups. The two were combined with each other to analyze the relationship between patients' clinical data and their impact on the prognosis.
RESULTS
KRAS mutations were found in 38.6% of the patients and 40.8% had a high p53 expression. There was no significant difference in the overall survival rate of patients, with or without KRAS gene mutations, and p53 expression level. In the group of patients with KRAS mutations, the survival time of patients with a high p53 expression was significantly lower than that of patients with a normal p53 expression (p = 0.020, log-rank test). Multivariate analysis showed that p53 high expression is an independent risk factor for the overall survival time of patients with KRAS mutations (HR = 2.330, 95% CI = 1.041-5.216, p < 0.05).
CONCLUSION
Colorectal cancer patients with KRAS mutations with a high p53 expression have a poor prognosis.
背景
在结直肠癌的发生和发展过程中，p53 是 MAPK 信号通路的重要下游调控因子，在抑制 KRAS 突变产生的异常增殖信号方面发挥重要作用。本研究旨在探讨 KRAS 突变与 p53 表达的相关性，并评估其在结直肠癌中的预后价值。
方法
采用 PCR 技术和免疫组化（IHC）染色法检测 266 例结直肠腺癌标本中 KRAS 基因突变状态和 p53 表达水平。根据 p53 表达水平将其分为高表达和正常组。KRAS 基因突变患者分为突变型和野生型组。将两者相结合，分析患者的临床资料与预后的关系。
结果
发现 38.6%的患者存在 KRAS 基因突变，40.8%的患者 p53 表达较高。有无 KRAS 基因突变以及 p53 表达水平对患者的总体生存率均无显著差异。在 KRAS 基因突变的患者组中，p53 高表达患者的生存时间明显短于 p53 正常表达患者（p=0.020，log-rank 检验）。多因素分析显示，p53 高表达是 KRAS 基因突变患者总生存时间的独立危险因素（HR=2.330，95%CI=1.041-5.216，p<0.05）。
结论
KRAS 基因突变合并 p53 高表达的结直肠癌患者预后不良。
Zotero 插件